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ABSTRACT 
 
Periodontal health is defined by absence of clinically detectable inflammation. There 
is a biological level of immune surveillance that is consistent with clinical gingival 
health and homeostasis. Clinical gingival health may be found in a periodontium that 
is intact, i.e. without clinical attachment loss or bone loss, and on a reduced 
periodontium in either a non-periodontitis patient (e.g. in patients with some forms of 
gingival recession or following crown lengthening surgery) or in a patient with a 
history of periodontitis who is currently periodontally stable. Clinical gingival health 
can be restored following treatment of gingivitis and periodontitis. However, the 
treated and stable periodontitis patient with current gingival health remains at 
increased risk of recurrent periodontitis and accordingly must be closely monitored.  
Two broad categories of gingival diseases include non-dental plaque biofilm-induced 
gingival diseases and dental plaque-induced gingivitis. Non-plaque induced gingival 
diseases include a variety of conditions that are not caused by plaque and usually do 
not resolve following plaque removal. Such lesions may be manifestations of a 
systemic condition or may be localized to the oral cavity. Dental plaque-induced 
gingivitis has a variety of clinical signs and symptoms, and both local predisposing 
factors and systemic modifying factors can affect its extent, severity and progression. 
Dental plaque-induced gingivitis may arise on an intact periodontium or on a reduced 
periodontium in either a non-periodontitis patient or in a currently stable “periodontitis 
patient” i.e. successfully treated, in whom clinical inflammation has been eliminated 
(or substantially reduced). A periodontitis patient with gingival inflammation remains 
a periodontitis patient (Figure 1), and comprehensive risk assessment and 
management are imperative to ensure early prevention and/or treatment of 
recurrent/progressive periodontitis. 
Precision dental medicine defines a patient-centered approach to care and therefore 
creates differences in the way in which a “case” of gingival health or gingivitis is 
defined for clinical practice as opposed to epidemiologically in population  
prevalence surveys. Thus, case definitions of gingival health and gingivitis are 
presented for both purposes. While gingival health and gingivitis have many clinical 
features, case definitions are primarily predicated on presence or absence of 
bleeding on probing. Here we classify gingival health and gingival 
diseases/conditions, along with a summary table of diagnostic features for defining 
health and gingivitis in various clinical situations.  
Periodontal health, gingival diseases and conditions on an intact 
and a reduced periodontium 
Workgroup 1: Periodontal Health & Gingival Diseases/ 
Conditions 
 
“Health is a state of complete physical, mental and social well-being and not merely the 
absence of disease or infirmity”.1 Based upon this definition from the World Health 
Organization (WHO), it follows that periodontal health should be defined as a state free 
from inflammatory periodontal disease that allows an individual to function normally and 
avoid consequences (mental or physical) due to current or past disease. Based upon this 
overall framework of health, periodontal health should be predicated upon the absence 
of disease, as assessed clinically, associated with gingivitis, periodontitis, or other 
periodontal conditions, and may include patients who have had a history of successfully 
treated gingivitis or periodontitis, or other periodontal conditions, who have been and 
are able to maintain their dentition without signs of clinical gingival inflammation.  
Additionally, clinical periodontal health embraces physiological immune surveillance 
involving levels of biological and inflammatory markers compatible with homeostasis.2 
Periodontitis is a chronic inflammatory disease that currently can be successfully 
controlled and teeth retained for life.  Periodontitis can remain stable (in remission) or 
enter periods of exacerbation.  A stable periodontitis patient remains at higher risk for 
recurrent disease compared to a gingivitis patient or a healthy patient. Therefore, 
precision dental medicine requires ongoing, individual risk assessment as part of optimal 
patient management.   
 
A definition of periodontal health and wellness is critical to establish ideal and acceptable 
therapeutic endpoints to periodontal therapies, to systematically assess the biological 
burden of periodontal inflammation to categorize gingival and periodontal disease 
prevalence in populations, and to evaluate individualized risk for future disease 
development. Periodontal health must be assessed and defined at both the patient and 
the site level to achieve these goals. Furthermore, definitions of periodontal health that 
are used to inform treatment decisions for individual patients may differ from those used 
in epidemiological studies. 
 
 
Is there a level of gingival inflammation that is consistent with clinical 
periodontal health at a site level?    
 
There is a biological level of immune surveillance, manifesting as a predominantly 
neutrophilic infiltrate that is consistent with clinical gingival health.2 
 
What is the spectrum of clinical periodontal health at a site level?  
 
What is the biology of clinical gingival health? 
 
Clinical gingival health is generally associated with an inflammatory infiltrate and a 
host response consistent with homeostasis. 
 
On a site level, how do we classify clinical gingival health? 
 
• Clinical gingival health on an intact periodontium 
• Clinical gingival health on a reduced periodontium 
o Stable periodontitis patient 
o Non-periodontitis patient (e.g. recession, crown lengthening) 
    
What are the clinical features of gingival health on an intact periodontium? 
 
Clinical gingival health on an intact periodontium is characterized by the absence of 
bleeding on probing, erythema and edema, patient symptoms, and attachment and 
bone loss.  Physiological bone levels range from 1.0 to 3.0 mm from the 
cementoenamel junction.   
What are the clinical features of gingival health on a reduced periodontium? 
 
Clinical gingival health on a reduced periodontium is characterized by an absence of 
bleeding on probing, erythema, edema and patient symptoms in the presence of 
reduced clinical attachment and bone levels. However, it should be recognized that 
successfully treated and stable periodontitis patients remain at increased risk of 
recurrent progression of periodontitis.  In non-periodontitis patients, there is no 
current evidence for increased risk of periodontitis. 
 
What are the clinical features of gingival health following treatment of gingivitis on an 
intact periodontium? 
 
Clinical gingival health following treatment of gingivitis on an intact periodontium is 
characterized by the absence of bleeding on probing, erythema and edema, patient 
symptoms, and attachment and bone loss.   
 
What are the clinical features of gingival health following successful treatment of 
periodontitis?  
 
Clinical gingival health following successful treatment of periodontitis is characterized 
by an absence of bleeding on probing, erythema, edema and patient symptoms in 
the presence of reduced clinical attachment and bone levels.  
 
Case Definitions for Periodontal Health and Gingivitis: 
Based on available methods to assess gingival inflammation, a gingivitis case can be 
simply, objectively and accurately defined and graded using a bleeding on probing 
score (BoP%),3 assessed as the proportion of bleeding sites (dichotomous yes/no 
evaluation) when stimulated by a standardized (dimensions and shape) periodontal 
probe with a controlled (~0.2 N) force to the apical end of the sulcus at 6 sites 
(mesio-buccal, buccal, disto-buccal, mesio-lingual, lingual, disto-lingual) on all teeth 
present.  Limitations of these clinical criteria arise from a lack of standardized 
periodontal probes (e.g. probe dimensions, taper), examiner variability (probe 
pressure, angle), patient related factors (biotype, medications, etc.) and smoking.   
In all references to an “intact periodontium” within this consensus, an absence of 
detectable attachment and/or bone loss is implicit.  
 
How do we define a case of gingival health on an intact and a reduced 
periodontium for epidemiological purposes? 
For an intact periodontium and a reduced and stable periodontium, gingival health is 
defined as <10% bleeding sites4,5 with probing depths ≤ 3mm.  
 How do we define a case of gingival health on an intact and a reduced 
periodontium for clinical practice? 
Due to limitations in, and a lack of uptake of, standardized ISO probes and 
techniques leading to inherent measurement variability in the parameters of gingival 
health, a patient with periodontal health may exhibit one or two sites with some 
evidence of clinical gingival inflammation. Moreover, localized mild and delayed 
bleeding to probe at isolated sites is ubiquitous, but may fall within the spectrum of 
“clinical health”. 
In clinical practice, a case of gingival health on an intact periodontium would be a 
patient with no signs of gingivitis as defined above.   
In clinical practice, the goal of periodontal treatment on a reduced periodontium is a 
patient with no signs of gingivitis as defined above.  A case of gingival health on a 
reduced periodontium in a stable periodontitis patient must be distinguished from a 
case of periodontal health in a reduced periodontium in a non-periodontitis patient 
(recession, crown lengthening), because there is a difference in risk for periodontal 
disease progression.  
Following treatment of periodontitis, periodontitis patients may not attain a status of 
complete gingival health based on the above definition. However, evidence has 
demonstrated that a patient may achieve periodontal stability. Periodontal stability is 
characterized by successful treatment through control of local and systemic risk 
factors, resulting in minimal (<10% of sites5) BOP, no probing depths of 4mm or 
greater that bleed on probing, optimal improvement in other clinical parameters and 
lack of progressive periodontal destruction. The treated and stable periodontitis 
patient with current gingival health remains at increased risk of recurrent periodontitis 
and accordingly must be closely monitored. Figure 1 summarizes the various 
scenarios that may arise following the transition from health, to gingivitis and 
ultimately periodontitis. 
 
How do we define gingivitis at a site level (biological & clinical)? 
 
Defining inflammation at a site level is quite distinct from defining a case of gingivitis. 
A universal case definition is essential to facilitate population surveillance, for 
clinicians setting therapeutic targets, and to enable assessment of the efficacy of 
prevention and/or treatment regimes. 
There are broadly two categories of gingival disease: 
• Dental plaque biofilm-induced gingivitis 
• Non-dental plaque-induced gingival diseases 
Dental plaque biofilm-induced gingivitis is defined at the site level as “an 
inflammatory lesion resulting from interactions between the dental plaque biofilm and 
the host’s immune-inflammatory response, which remains contained within the 
gingiva and does not extend to the periodontal attachment (cementum, periodontal 
ligament and alveolar bone). Such inflammation remains confined to the gingiva and 
does not extend beyond the mucogingival junction and is reversible by reducing 
levels of dental plaque at and apical to the gingival margin”.   
Depending on whether dental plaque biofilm-induced gingival inflammation occurs on 
an intact or reduced periodontium, or in a patient diagnosed with periodontitis, 
gingivitis can be further classified as:  
• Gingivitis on an intact periodontium 
• Gingivitis on a reduced periodontium in a non-periodontitis patient (e.g. recession, 
crown lengthening)  
• Gingival inflammation on a reduced periodontium in a successfully treated 
periodontitis patient (Note that recurrent periodontitis cannot be ruled out in this 
case) 
 
Since the 1999 classification, there have been advances in knowledge of the 
microbiome and the gingival transcriptome. Gingivitis is a non-specific inflammatory 
condition and is therefore a consequence of sustained plaque biofilm accumulation 
at and apical to the gingival margin7. Longitudinal studies have demonstrated that 
sites that do not progress to attachment loss are characterized by less gingival 
inflammation over time, whereas those sites that do progress have persistently 
greater levels of gingival inflammation8-13, 14. Therefore, gingivitis is a major risk 
factor, and a necessary pre-requisite, for periodontitis. The management of gingivitis 
is thus a primary prevention strategy for periodontitis. 
Periodontitis patients who are currently stable but develop gingival inflammation at 
specific sites should remain on periodontal maintenance and should be closely 
monitored during periodontal maintenance for any reactivation of periodontitis. Such 
patients may not be managed in the same way as non-periodontitis patients with 
gingivitis.   
 
What are the determinants of the rate of development of gingivitis, its severity 
and extent? 
The threshold of plaque accumulation necessary to induce gingival inflammation and 
impact upon its rate of progression at specific sites or at a whole mouth level varies 
between individuals according to both local risk factors, known as predisposing 
factors, and systemic risk factors, referred to as modifying factors, respectively. 
1) Local risk factors (predisposing factors) 
Local risk factors for gingivitis are those that encourage plaque accumulation at a 
specific site by either inhibiting its removal during daily oral hygiene practices, and/or 
creating a biological niche that encourages increased plaque accumulation7. These 
include: 
a) Dental plaque biofilm retention factors (including certain tooth anatomical 
factors) – facilitate plaque accumulation at and apical to the gingival margin, 
enabling biofilm adherence and maturation and increasing the difficulty of 
mechanical plaque removal. Several clinical studies providing a moderate 
level of evidence have demonstrated that sub-gingival restoration margins 
may be detrimental to gingival health15, 16. 
 
b) Oral dryness is a clinical condition often associated with symptoms of 
xerostomia.  Oral dryness manifesting as a lack of salivary flow, availability, or 
changes in quality of saliva, leading to reduced cleansing of tooth surfaces is 
associated with reduced dental plaque biofilm removal and enhanced gingival 
inflammation. Common causes include medications that have anti-
parasympathetic action, Sjögrens syndrome when the salivary acini are 
replaced by fibrosis following autoimmune destruction, and mouth breathing in 
people who may have enhanced gingival display and/or an incompetent lip 
seal17. 
 
2) Systemic risk factors (modifying factors) 
Systemic risk or modifying factors are those characteristics present in an individual, 
which negatively influence the immune-inflammatory response to a given dental 
plaque biofilm burden, resulting in exaggerated or “hyper” inflammation. Examples 
include: 
a) Smoking – is one of the major lifestyle/behavioral risk factors for periodontitis, 
but which also has profound effects upon the gingival tissues. Systemic 
circulatory uptake of components of cigarette smoke as well as local uptake 
are reported to induce microvascular vasoconstriction and fibrosis. This can 
mask clinical signs of gingivitis, such as bleeding on probing, despite a 
significant underlying pathological inflammatory cell infiltrate18.  
 
b) Metabolic factors – hyperglycemia in people with or without diabetes.  Excess 
glucose is toxic and directly induces mitochondrial stress and an enhanced 
respiratory burst in inflammatory cells that may activate various pro-
inflammatory mediator cascades. Formation of advanced glycation end-
products (AGEs) may also result in AGE binding to its cell surface receptor 
(RAGE), which activates pro-inflammatory signaling cascades and 
downstream pro-inflammatory events. 
 
c) Nutritional factors - Severe vitamin C deficiency, or scurvy, results in 
compromised antioxidant micronutrient defenses to oxidative stress and also 
negatively impacts collagen synthesis, resulting in weakened capillary blood 
vessel walls and a consequent propensity to enhanced gingival bleeding20. 
 
d) Pharmacological agents (prescription, non-prescription and recreational 
agents) – can act via diverse mechanisms to increase susceptibility to 
gingivitis. This may include drugs that reduce salivary flow, drugs that impact 
endocrine function (see below), and drugs that may induce gingival 
enlargement and pseudo-pocketing. 
 
e) Elevations in sex steroid hormones – at puberty, during pregnancy or 
following medication with first generation oral contraceptives may modify the 
gingival inflammatory response. Complex biological reactions within the 
gingival tissues result from such elevated sex steroid levels and generate 
more than expected inflammation, in response to relatively small levels of 
plaque. However, modern oral contraceptive dosages have been reduced and 
there is little evidence for exaggerated gingival inflammatory responses to 
plaque with such drugs21. 
 
f) Hematological conditions – particular blood malignancies such as leukemia or 
pre-malignant conditions such as myelodysplasia are associated with signs of 
excess gingival inflammation in the absence of excessive plaque biofilm 
accumulation. Signs include swollen, purple or occasionally pale gingiva due 
to leukemic cell infiltration, gingival bleeding that is inconsistent with levels of 
dental plaque biofilm accumulation, due to thrombocytopenia and/or clotting 
factor deficiencies22. 
 
What are the diagnostic criteria for a gingivitis case? 
Given the “spectrum” of presentation of gingival health and gingival inflammation in 
terms of severity and extent of gingival involvement, it is important to define the 
features of a universally accepted case of gingivitis. 
Current epidemiological data on the prevalence of gingivitis suffer from the lack of a 
universally adopted case definition and vary as widely as 6% to 94%, due to the use 
of indices that measure gingival inflammation at individual sites rather than 
considering the patient’s mouth as a whole. Therefore, mild localized clinical 
inflammation is reported to affect almost 95% of the population, a figure that would 
incorrectly suggest gingivitis as being a variation of “normality” and thus consistent 
with the spectrum of “clinical health” rather than being a disease. By contrast, the 
more extensive the manifestation of disease employed in a case definition, the lower 
the reported prevalence. A universally agreed case definition should be based upon 
a pragmatic appraisal of the evidence base derived from longitudinal observation 
and intervention studies.  
Clinical, radiological, biological signs and symptoms 
 
1. Gingivitis is a clinical diagnosis.  While emerging technologies are starting to 
shed light on the microbiological, molecular and pathophysiological 
characteristics of gingivitis, definitive knowledge is not sufficient to supersede 
current clinical parameters7. 
2. The clinical signs of inflammation are erythema, edema, pain (soreness), heat 
and loss of function. 
3. These may manifest clinically in gingivitis as  
a. Swelling, seen as loss of knife edged gingival margin and blunting of 
papillae 
b. Bleeding on gentle probing 
c. Redness 
d. Discomfort on gentle probing 
4. The symptoms a patient may report include 
a. Bleeding gums (metallic/altered taste) 
b. Pain (soreness) 
c. Halitosis 
d. Difficulty eating 
e. Appearance (swollen red gums) 
f. Reduced oral health related quality of life 
5. Radiographs cannot be used to diagnose gingivitis. 
 
Should we classify dental plaque biofilm-induced gingivitis? 
There is utility in defining the severity of gingivitis as a patient communication tool, but 
there are no objective clinical criteria for defining severity.  Thus, in this context alone, 
the extent of gingivitis can be used to communicate “mild, moderate and severe” 
gingivitis.  Moreover, emerging evidence suggests that the contained gingivitis lesion 
may have systemic inflammatory consequences23,24. 
 
There is no robust evidence to clearly differentiate mild, moderate and severe gingivitis 
and definitions remain a matter of professional opinion.  Methods of defining gingivitis 
may include: 
1. Defining percentages (e.g. mild = <10%, moderate = 10-30%, severe = >30% 
sites) 
2. Grading (e.g. grade 1-5 in 20% quintiles for % sites bleeding on probing)  
 
How do we define a case of dental plaque-induced gingivitis on an intact and 
a reduced periodontium for epidemiological purposes? 
For epidemiological purposes, gingivitis on an intact periodontium and gingivitis on a 
reduced periodontium in a patient without a history of periodontitis, is defined as 
≥10% bleeding sites4,5 with probing depths ≤3mm. Localized gingivitis is defined as 
10%-30% bleeding sites; generalized gingivitis is defined as >30% bleeding sites. 
For epidemiological purposes alone, a periodontitis case cannot simultaneously be 
defined as a gingivitis case. Therefore, a patient with a history of periodontitis, with 
gingival inflammation is still a periodontitis case.   
 
How do we classify a patient with dental plaque-induced gingivitis on an intact 
and a reduced periodontium for clinical practice? 
In clinical practice, a case of gingivitis on an intact periodontium, or a reduced 
periodontium in a patient without a history of periodontitis, would be a patient with 
signs of gingival inflammation as defined above (Table 1).  
In clinical practice, periodontitis patients, if successfully treated can achieve a 
reduced and stable periodontium where probing pocket depths are ≤4mm27 and 
there is an absence of clinical inflammation (bleeding on probing). Gingival 
inflammation may arise at specific sites, and where probing depths are <3mm is 
termed gingival inflammation in a stable periodontitis patient. However, such patients 
remain at high risk of recurrent periodontitis and require close monitoring as such 
sites are at high risk of reverting to periodontitis (Table 1).  
 
How do we classify non-dental plaque-induced gingival conditions? 
Although oral health and systemic health are frequently considered as separate 
entities, both are strongly interrelated. There are numerous examples of how oral 
diseases may impact systemic health and how the oral cavity may be a window to 
general health. Consequently, it is crucial for all health care providers to understand 
these interrelationships, inform patients of such conditions, and make appropriate 
referrals.  
Non dental-plaque induced gingival conditions encompass a variety of conditions 
that are not caused by plaque and usually do not resolve following plaque removal. 
Such lesions may be manifestations of a systemic condition or may be localized to 
the oral cavity25. Although these lesions are not caused by the dental plaque biofilm, 
the severity of the clinical manifestations often depends on plaque accumulation and 
subsequent gingival inflammation26. 
The proposed classification considers those conditions listed in Table 2. 
 
Which non-dental-plaque-induced gingival conditions may have associated 
systemic involvement and how does that impact upon patient-centered care 
pathways? 
In recent years, the traditional treatment model in which the patient was a passive 
receiver of care is changing toward patient-centered care in Precision Dental 
Medicine (PDM).  In PDM, an individual’s specific health needs and desired health 
outcomes are the driving force behind all health care decisions and quality 
measurements. One of the elements in PDM is that care is collaborative, coordinated 
and accessible. The right care is provided at the right time and the right place. 
Considering that the conditions marked with an asterisk (Table 2) have associated 
systemic involvement or are oral manifestations of systemic conditions, other health 
care providers may be involved in diagnosis and treatment. 
 
Future Research Needs 
Regarding classification and diagnosis of periodontal health and gingival 
diseases/conditions, future research is needed on the:  
• development and validation of non-invasive diagnostic tools (e.g., saliva-
based diagnostics), especially as they relate to detection of gingival 
inflammation;  
• identification of the characteristics (e.g., genetic factors) that distinguish 
persons who are resistant to the development of dental plaque biofilm-
induced or non-dental plaque biofilm-induced gingival diseases from those 
who are susceptible;  
• expansion of our limited knowledge of the determinants that affect the 
reliability of currently available diagnostic tools (e.g., effects of probe design 
on bleeding on probing responses);  
• characterization of the possible differences (e.g., molecular determinants) 
between gingivitis on an intact periodontium and other forms of gingival 
inflammatory disease.   
 
Regarding the current primary periodontal diagnostic tool, the graduated periodontal 
measuring probe, the following are recommendations for an ISO periodontal probe: 
The reliability and reproducibility of any case definition for health, gingival or 
periodontal conditions relies upon standardization of probing protocols, which is only 
possible with the implementation of an ISO probe. The current International standard 
for organization (ISO) for periodontal probes is - ISO 21672, but requires updating in 
order to define the features of a global standard periodontal probe. These 
characteristics are: 
1. Tip diameter 0.5mm 
2. Cylindrical tine structure 
3. Constant force limiter of 0.2N 
4. 15mm scale with precise individual or banded millimeter markings 
5. A taper of 1.75° 
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Figure 1 
 
 
Figure Legend:    
The transition from periodontal health to gingivitis is reversible following treatment that resolves gingival inflammation. The transition to periodontitis 
results in attachment loss which, at the present time is irreversible. More importantly, it signposts patients who are at lifelong high risk of recurrent 
periodontitis. Optimal periodontal therapy can restore gingival health on a reduced periodontium, or may result in mild marginal gingival inflammation at 
shallow probing pocket depths (<3mm). However, a history of periodontitis places patients at high risk of recurrent periodontitis and such patients require 
careful site-specific monitoring during periodontal maintenance programs.
 Table 1 
Diagnostic look up table for gingival health or dental plaque-
induced gingivitis in clinical practice. 
 
Intact periodontium Health Gingivitis 
Probing attachment loss No No 
Probing pocket depths 
(assuming no pseudo pockets) 
<3mm <3mm 
Bleeding on probing <10% Yes (>10%) 
Radiological bone loss No No 
Reduced periodontium 
Non periodontitis patient 
Health Gingivitis 
Probing attachment loss Yes Yes 
Probing pocket depths 
(all sites & assuming no 
pseudo pockets) 
<3mm <3mm 
Bleeding on probing  <10% Yes (>10%) 
Radiological bone loss Possible Possible 
 
NB: In conditions where there is treatment but not cure, e.g. rheumatoid arthritis, 
periodontitis, the post-treatment parameters that define stability/health or gingivitis may 
differ from the parameters for health/gingivitis in a non-periodontitis patient. The threshold 
for “clinical health” in a treated and stable periodontitis patient is therefore set at <4mm. 
 
Successfully treated stable 
periodontitis patient 
Health Gingivitis in a patient with 
a history of periodontitis 
Probing attachment loss Yes Yes 
Probing pocket depths 
(all sites & assuming no 
pseudo pockets)  
<4mm 
(no site > 4mm with 
BoP)** 
<3mm 
Bleeding on probing  <10% Yes (>10%) 
Radiological bone loss Yes Yes 
NB: A successfully treated periodontitis patient in whom sites of gingival bleeding appear, 
remains at high risk of disease recurrence at those sites and of progressive attachment 
loss. Therefore, gingivitis is defined as bleeding at a shallow site of <3mm rather than 
<4mm, as is the case in gingival heath. Where the probing depth is 4mm or higher with 
bleeding, this is no longer a “closed pocket 21 
 
* Assumes a light probing pressure of 0.2-0.25N 
** There was a rational minority view expressed that the threshold for defining a clinical case of health 
in a successfully treated periodontitis patient should be set at <3mm with no BoP to acknowledge the 
elevated risk of recurrent disease. However, the counter and majority view was that the <3mm 
threshold is rarely achieved at 100% of treated sites and could lead to over-treatment, since any non-
bleeding site >3mm would not be classified as “health” and thus open to further invasive treatment, 
rather than monitoring and supportive care. The threshold was therefore set at <4mm acknowledging 
that post-treatment clinical phenotypes need to be considered differently to pre-treatment phenotypes. 
  
Table 2 
Classification of gingival health and gingival diseases/conditions 
 
1. Periodontal Health2   
   
A. Clinical health on an intact periodontium 
 
  
B. Clinical gingival health on a reduced periodontium 
i) Stable periodontitis patient 
ii) Non-periodontitis patient 
 
  
   
2. Gingivitis – dental plaque-induced: Intact periodontium; Reduced periodontium in 
non-periodontitis patient; Reduced periodontium in successfully treated periodontitis 
patient.7 
  
   
A. Associated with biofilm alone   
   
B. Mediated by systemic or local risk factors 
 
  
 i) Systemic risk factors (Modifying factors)  
 a) Smoking  
 b) Hyperglycemia  
 c) Nutritional Factors  
 d) Pharmacological agents (prescription, non-prescription and recreational)  
 e) Sex steroid hormones  
 Puberty  
 Menstrual cycle  
 Pregnancy  
 Oral contraceptives  
 f) Hematological conditions  
   
 ii) Local risk factors (Predisposing factors)  
 a) Dental plaque biofilm retention factors (e.g., prominent restoration margins)  
 b) Oral dryness  
   
C. Drug-influenced gingival enlargement   
 
 
3. Gingival diseases - Non-dental plaque-induced25   
   
A. Genetic/Developmental Disorders   
   
 i) Hereditary gingival fibromatosis *  
   
B. Specific Infections 
 
  
 i) Bacterial origin  
 a) Neisseria gonorrhea *  
 b) Treponema pallidum *  
 c) Mycobacterium tuberculosis *  
 d) Streptococcal gingivitis  
   
 ii) Viral origin  
 a) Coxsackie virus (Hand foot and mouth disease) *  
 b) Herpes simplex I & II (primary or recurrent) *  
 c) Varicella zoster (Chicken pox & shingles – V nerve) *  
 d) Molluscum contageosum *  
 e) Human papilloma virus (squamous cell papilloma; Condyloma acuminatum; 
Verruca vulgaris; focal epithelial hyperplasia) 
 
   
 iii) Fungal origin  
 a) Candidosis   
 f) Other mycoses (e.g. Histoplasmosis; Aspergillosis  
    
C. Inflammatory and immune conditions 
 
  
 i) Hypersensitivity reactions  
 a) Contact allergy *  
 b) Plasma cell gingivitis *  
 c) Erythema multiforme *  
   
 ii) Autoimmune diseases of skin and mucous membranes  
 a) Pemphigus vulgaris *  
 b) Pemphigoid *  
 c) Lichen planus *  
 d) Lupus erythematosus *  
 Systemic lupus erythematosis  
 Discoid lupus erythematosis  
   
 iii) Granulomatous inflammatory lesions (oro-facial granulomatoses)  
 e) Crohn’s disease *  
 f) Sarcoidosis *  
   
D. Reactive processes 
 
  
   
 i) Epulides  
 a) Fibrous epulis  
 b) Calcifying fibroblastic granuloma  
 c) Vascular epulis (pyogenic granuloma)  
 d) Peripheral giant cell granuloma *  
    
E. Neoplasms 
 
  
   
 i) Premalignancy  
 a) Leukoplakia  
 b) Erythroplakia   
   
 ii) Malignancy  
 a) Squamous cell carcinoma *  
 b) Leukemic cell infiltration *  
 c) Lymphoma *  
 Hodgkins  
 Non-Hodgkins  
   
F. Endocrine, nutritional & metabolic diseases 
 
  
   
 i) Vitamin deficiencies *  
 a) Vitamin C deficiency (scurvy)  
   
G. Traumatic lesions 
 
  
 i) Physical/mechanical trauma  
 a) Frictional keratosis  
 b) Mechanically induced gingival ulceration  
 c) Factitious injury (self-harm)  
   
 ii) Chemical (toxic) burn  
   
 iii) Thermal insults  
 a) Burns to gingiva  
   
H. Gingival pigmentation 
 
  
 i) Melanoplakia *  
 ii) Smokers melanosis  
 iii) Drug-induced pigmentation (anti-malarials, minocycline)  
 iv) Amalgam tattoo  
 
* Conditions marked with an asterisk have associated systemic involvement or are oral 
manifestations of systemic conditions, therefore other health care providers may be involved 
in diagnosis and treatment. 
